Personalized Comorbidity-Integrated Gout Care

候选人：Chio Yokose，医学博士，硕士，哈佛医学院(HMS)医学讲师， 马萨诸塞州总医院风湿病、过敏和免疫科医学助理 医院(MGH)。布朗大学毕业后，以优异成绩获得生物学和东亚专业学士学位 在学习期间，她获得了西北大学的医学博士学位。她完成了她的内科实习医生在 纽约大学和她在麻省理工学院的风湿病研究员。她还获得了哈佛大学流行病学硕士学位。 哈佛大学公共卫生学院。Yokose博士进行以患者为中心的研究，重点是痛风 和它的心脏代谢合并症在Hyon Choi，MD，DrPH的指导下。她的研究结果是 在17份同行评议的原稿中(8份为第一作者)。她的目标是成为一名独立人士。 以患者为中心的个性化痛风研究的研究者和领导者。 指导、培训活动和环境：Yokose博士将在麻省理工学院领导拟议的项目 在Hyon Choi，MD，DrPH的指导下，David W.Bates，MD，MSc和Maria Edelen的共同指导下， 博士学位。崔博士是美国国立卫生研究院资助的世界知名内科研究员，在高级流行病学方面具有专业知识。 事件痛风的方法和风险因素。贝茨博士是一位卓越的医疗杠杆专家 进行患者安全、质量和临床效果研究的信息学。埃德伦医生有广泛的 在制定、实施、分析和解释患者报告结果方面的专业知识 措施(PROM)。崔博士、贝茨博士和埃德伦博士都有指导学员和初级学员的丰富经验。 教职员工，包括多名以前的K奖获得者。Yokose博士还将受益于她的钥匙的特定专业知识 合作者，包括药物流行病学方法和潜伏期分析。在她的指导下 指导团队，她将在新的研究领域获得技能，包括比较有效性研究， 使用真实世界数据的研究，以及使用生物标记物和PROM的以患者为中心的结果研究。 研究：痛风及其心脏代谢合并症的发病率和死亡负担持续上升。 这些趋势突显了我们目前痛风护理模式的局限性，在这种模式中，痛风和并存 独立管理。这项研究的中心目标是检查多效性痛风的益处。 心脏代谢药物，并确定痛风和共病的个性化整合框架 注意协同解决痛风和并存问题，并最终改善痛风患者的预后。 为了实现这一目标，Yokose博士将进行严格的比较有效性研究，检查血清尿酸- 降低常见心脏代谢药物的潜力(目标1)并确定 痛风事件及其与血尿酸变化(痛风的关键致病前兆)和胎膜早破的关系 痛风护理障碍(目标2)。通过完成这个计划和培训计划，Yokose博士将获得重要的经验 成为一名独立的临床研究人员和个性化、以患者为导向的痛风研究的领导者。

Candidate: Chio Yokose, MD, MSc is an Instructor in Medicine at Harvard Medical School (HMS) and an Assistant in Medicine in the Division of Rheumatology, Allergy, and Immunology at Massachusetts General Hospital (MGH). After graduating Brown University magna cum laude with her BA in Biology and East Asian Studies, she received her MD from Northwestern University. She completed her internal medicine residency at New York University and her rheumatology fellowship at MGH. She also received her MSc in Epidemiology from the Harvard T.H. Chan School of Public Health. Dr. Yokose conducts patient-centered research focused on gout and its cardiometabolic comorbidities under the mentorship of Hyon Choi, MD, DrPH. Her research has resulted in 17 peer-reviewed original manuscripts (eight as first-author). Her goal is to become an independent investigator and leader in personalized, patient-centered gout research. Mentorship, Training Activities, and Environment: Dr. Yokose will conduct the proposed project at MGH under the mentorship of Hyon Choi, MD, DrPH and co-mentorship of David W. Bates, MD, MSc and Maria Edelen, PhD. Dr. Choi is a world-renowned, NIH-funded physician investigator with expertise in advanced epidemiologic methodologies and risk factors for incident gout. Dr. Bates is a preeminent expert on leveraging medical informatics to conduct patient safety, quality, and clinical effectiveness research. Dr. Edelen has extensive expertise in the development, implementation, analysis, and interpretation of patient-reported outcomes measures (PROMs). Drs. Choi, Bates, and Edelen all have extensive experience mentoring trainees and junior faculty, including multiple prior K awardees. Dr. Yokose will also benefit from the specific expertise of her key collaborators, including pharmacoepidemiology methods and latent class analysis. Under the guidance of her mentorship team, she will acquire skills in new research areas including comparative effectiveness research, research using real-world data, and patient-centered outcomes research using biomarkers and PROMs. Research: The morbidity and mortality burden of gout and its cardiometabolic comorbidities continues to rise. These trends highlight the limitations of our current gout care model in which gout and comorbidities are managed independently. The central goal of this research is to examine the gout benefits of pleiotropic cardiometabolic medications and identify a framework for the personalized integration of gout and comorbidity care to synergistically address gout and comorbidities and ultimately improve outcomes for patients with gout. To achieve this, Dr. Yokose will conduct rigorous comparative effectiveness research examining the serum urate- lowering potential of common cardiometabolic medications (Aim 1) and determine comorbidity phenotypes of incident gout and their relations with serum urate change (key causal precursor to gout) and PROMs related to gout care barriers (Aim 2). By completing this proposal and training plan, Dr. Yokose will gain critical experience to become an independent clinical researcher and leader in personalized, patient-oriented gout research.